Dr Charlotte Brierley
MA, BM BCh, MRCP
Wellcome Trust Clinical Research Fellow
Investigating the cellular and genetic landscape of myeloid neoplasms
I am a Wellcome Trust Clinical Research Fellow, working towards a DPhil in the haematopoietic stem cell biology group supervised by Prof Adam Mead and Dr Bethan Psaila. I am currently completing a visiting fellowship to Dr Elli Papaemmanuil’s group at Memorial Sloan Kettering Cancer Centre in New York.
I completed my undergraduate degree in medical sciences at the University of Cambridge and subsequent clinical medical training at Oxford. After qualifying I was awarded an NIHR Academic Foundation post in Edinburgh, after which I returned to Oxford as an Academic Clinical Fellow, allowing me to continue my research work alongside completing clinical training in haematology.
My research aims to understand how patients with acute myeloid leukaemia (AML) develop the disease, and why some respond to treatment better than others. My project uses single cell approaches to understand the genomic, proteomic and transcriptomic changes in blast-phase myeloproliferative neoplasms, a particularly aggressive type of AML. More widely, we hope that understanding the mechanisms of disease development, progression and response to therapy will lead to the identification of novel therapeutic targets to help patients with this disease.
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes.
Brierley CK. et al, (2020), Cancer, 126, 4735 - 4743
Single-cell sequencing in hematology.
Brierley CK. and Mead AJ., (2020), Curr Opin Oncol, 32, 139 - 145
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).
Sharrack B. et al, (2020), Bone Marrow Transplant, 55, 283 - 306
Sugar thieves and addicts: nutrient subversion in JAK2 MPNs.
Brierley CK. and Psaila B., (2019), Blood, 134, 1778 - 1780
The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
Brierley CK. et al, (2019), Transfusion, 59, 2248 - 2254